

Thomas Klimkait

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9548789/publications.pdf>

Version: 2024-02-01

68
papers

2,303
citations

293460

24
h-index

263392

45
g-index

72
all docs

72
docs citations

72
times ranked

3482
citing authors

#	ARTICLE	IF	CITATIONS
1	Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho. <i>HIV Medicine</i> , 2023, 24, 153-162.	1.0	3
2	Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). <i>HIV Medicine</i> , 2022, 23, 287-293.	1.0	16
3	The <i>Petasites hybridus</i> CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro. <i>Viruses</i> , 2022, 14, 106.	1.5	4
4	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. <i>Viruses</i> , 2022, 14, 406.	1.5	1
5	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	0
6	HPLC-Based Purification and Isolation of Potent Anti-HIV and Latency Reversing Daphnane Diterpenes from the Medicinal Plant <i>Gnidia sericocephala</i> (Thymelaeaceae). <i>Viruses</i> , 2022, 14, 1437.	1.5	1
7	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	2.9	10
8	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab046.	0.4	0
9	Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1294-1298.	1.3	11
10	Adapting the geno2pheno[coreceptor] tool to HIV-1 subtype CRF01_AE by phenotypic validation using clinical isolates from South-East Asia. <i>Journal of Clinical Virology</i> , 2021, 136, 104755.	1.6	1
11	Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003839.	3.9	8
12	The Suboptimal Pediatric HIV Viral Load Cascade. <i>Pediatric Infectious Disease Journal</i> , 2021, Publish Ahead of Print, .	1.1	3
13	Engagement in Care, Viral Suppression, Drug Resistance, and Reasons for Nonengagement After Home-Based Same-Day Antiretroviral Therapy Initiation in Lesotho: A Two-Year Follow-up of the CASCADE Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 2608-2614.	2.9	15
14	Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania. <i>BMC Infectious Diseases</i> , 2020, 20, 773.	1.3	2
15	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	0.9	7
16	Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial. <i>Lancet HIV</i> , 2020, 7, e752-e761.	2.1	21
17	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. <i>PLoS Medicine</i> , 2020, 17, e1003325.	3.9	16
18	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	5.8	5

#	ARTICLE	IF	CITATIONS
19	High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania – A prospective cohort study. PLoS ONE, 2020, 15, e0227600.	1.1	8
20	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980–2018. Antiviral Therapy, 2020, 25, 43-54.	0.6	2
21	Title is missing!. , 2020, 17, e1003325.		0
22	Title is missing!. , 2020, 17, e1003325.		0
23	Title is missing!. , 2020, 17, e1003325.		0
24	Title is missing!. , 2020, 17, e1003325.		0
25	The HOSENG trial – Effect of the provision of oral self-testing for absent and refusing individuals during a door-to-door HIV-testing campaign on testing coverage: protocol of a cluster-randomized clinical trial in rural Lesotho. Trials, 2019, 20, 496.	0.7	6
26	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	5.8	112
27	VIBRA trial – Effect of village-based refill of ART following home-based same-day ART initiation vs clinic-based ART refill on viral suppression among individuals living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. Trials, 2019, 20, 522.	0.7	9
28	The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. PLoS ONE, 2019, 14, e0220337.	1.1	41
29	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	1.9	6
30	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	1.9	27
31	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	1.3	9
32	Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho. JAMA - Journal of the American Medical Association, 2018, 319, 1103.	3.8	199
33	Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa. Scientific Reports, 2018, 8, 2363.	1.6	10
34	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	2.2	17
35	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	3.5	37
36	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	13.7	47

#	ARTICLE	IF	CITATIONS
37	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.4	8
38	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	4.2	29
39	Performance Evaluation of a Genotypic Tropism Test Using HIV-1 CRF01_AE Isolates in Japan. <i>Japanese Journal of Infectious Diseases</i> , 2018, 71, 264-266.	0.5	3
40	SESOTHO trial (‘‘Switch Either near Suppression Or THOUSAND’’) – switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa. <i>BMC Infectious Diseases</i> , 2018, 18, 76.	1.3	6
41	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. <i>PLoS Pathogens</i> , 2018, 14, e1006895.	2.1	53
42	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2069-2074.	1.3	11
43	MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. <i>Journal of Virological Methods</i> , 2017, 240, 7-13.	1.0	49
44	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. <i>Retrovirology</i> , 2017, 14, 33.	0.9	16
45	Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. <i>Clinical Infectious Diseases</i> , 2017, 64, 295-300.	2.9	14
46	When patients fail UNAIDS™ last 90 – the ‘‘failure cascade’’ beyond 90–90–90 in rural Lesotho, Southern Africa: a prospective cohort study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21803.	1.2	23
47	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	2.8	16
48	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017, 147, w14485.	0.8	27
49	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	15.2	133
50	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016, 13, 62.	0.9	45
51	Should viral load thresholds be lowered?. <i>Medicine (United States)</i> , 2016, 95, e3985.	0.4	36
52	Same day ART initiation versus clinic-based pre-ART assessment and counselling for individuals newly tested HIV-positive during community-based HIV testing in rural Lesotho – a randomized controlled trial (CASCADE trial). <i>BMC Public Health</i> , 2016, 16, 329.	1.2	35
53	A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv199.	0.4	3
54	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	2.9	60

#	ARTICLE	IF	CITATIONS
55	Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? <i>Tropical Medicine and International Health</i> , 2015, 20, 914-918.	1.0	17
56	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	1.9	61
57	Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. <i>PLoS Pathogens</i> , 2015, 11, e1004722.	2.1	68
58	A Diagnostic HIV-1 Tropism System Based on Sequence Relatedness. <i>Journal of Clinical Microbiology</i> , 2015, 53, 597-610.	1.8	8
59	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	2.9	75
60	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. <i>American Journal of Epidemiology</i> , 2014, 179, 1514-1525.	1.6	25
61	Estimating the Basic Reproductive Number from Viral Sequence Data. <i>Molecular Biology and Evolution</i> , 2012, 29, 347-357.	3.5	206
62	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. <i>Journal of Translational Medicine</i> , 2011, 9, 14.	1.8	8
63	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
64	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. <i>Aids</i> , 2010, 24, 1177-1183.	1.0	62
65	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	1.9	172
66	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	2.1	108
67	African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009, 23, 1269-1276.	1.0	28
68	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.	1.0	117